Most cited papers from Michalski Huettermann and Partner
What are the most cited papers from Michalski Huettermann and Partner?
The most cited paper from Michalski Huettermann and Partner is "Intellectual property protection" (Ulrich Storz, 2011), with 118 citations. Next come "Pulmonary Artery Banding for Functional Regeneration of End-Stage Dilated Cardiomyopathy in Young Children" (63) and "Rituximab" (41).
Showing 50 of 60 papers. Every paper is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Intellectual property protection Ulrich Storz · mAbs | May 2011 | 118 |
| 2 | Pulmonary Artery Banding for Functional Regeneration of End-Stage Dilated Cardiomyopathy in Young Children Dietmar Schranz et al. · Circulation | 26 Mar 2018 | 63 |
| 3 | Rituximab Ulrich Storz · mAbs | 7 May 2014 | 41 |
| 4 | Contact-free single-cell cultivation by negative dielectrophoresis Magnus Sebastian Jaeger, Katja Uhlig, Thomas Schnelle et al. · Journal of Physics D Applied Physics | 8 Aug 2008 | 37 |
| 5 | Antibody-drug conjugates: Intellectual property considerations Ulrich Storz · mAbs | 20 Aug 2015 | 17 |
| 6 | The patent maze of COVID 19 vaccines Ulrich Storz · Expert Opinion on Therapeutic Patents | 18 Jun 2021 | 15 |
| 7 | Synthesis and characterization of cBN/WCCo composites obtained by the pulse plasma sintering (PPS) method A. Michalski, Marcin Rosinski, Magdalena Płocińska et al. · IOP Conference Series Materials Science and Engineering | 21 Sep 2011 | 13 |
| 8 | The COVID-19 vaccine patent race Ulrich Storz · Nature Biotechnology | Jul 2022 | 12 |
| 9 | Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope Colin G. Sandercock, Ulrich Storz · Nature Biotechnology | Jul 2012 | 11 |
| 10 | CRISPR Cas9 − Licensing the unlicensable Ulrich Storz · Journal of Biotechnology | 15 Nov 2017 | 10 |
| 11 | An update on obtaining and enforcing therapeutic antibody patent claims Theresa Gresl, Ulrich Storz, Colin G. Sandercock · Nature Biotechnology | Dec 2016 | 10 |
| 12 | The CRISPR Cas patent files, part 1: Cas9 – Where to we stand at the 10 year halftime? Ulrich Storz · Journal of Biotechnology | 19 Nov 2023 | 8 |
| 13 | Transport of a charge carrier packet in nanoparticulate ZnO electrodes Volker Noack, Horst Weller, Alexander Eychmüller · Physical Chemistry Chemical Physics | 2003 | 8 |
| 14 | IP Issues of Therapeutic Antibodies Ulrich Storz, Wolfgang Flasche, Johanna Driehaus · SpringerBriefs in biotech patents | 2012 | 8 |
| 15 | IP Issues in the Therapeutic Antibody Industry Ulrich Storz | 2010 | 7 |
| 16 | International intellectual property strategies for therapeutic antibodies Ulrich Storz · mAbs | Nov 2011 | 6 |
| 17 | Kryptoverwahrung nach dem KWG: Der Versuch einer Konturierung des neuen Erlaubnistatbestands Daniel Resas, Niklas Ulrich, A. de Boer van der Geest · Zeitschrift für Bankrecht und Bankwirtschaft | 15 Feb 2020 | 4 |
| 18 | A Portfolio Management Approach in Accounts Receivable Management Grzegorz Marek Michalski · South East European Journal of Economics and Business | 2008 | 4 |
| 19 | Subordination of Shareholder Loans from a Legal and Economic Perspective Martin Gelter, Jürg Roth · RePEc: Research Papers in Economics | 2007 | 4 |
| 20 | Patent Lifecycle Management, Supplementary Protection Certificates and Data Exclusivity in Biopharmaceutics Ulrich Storz · SpringerBriefs in biotech patents | 2012 | 4 |
| 21 | Redefining antibody patent protection using paratope mapping and CDR-scanning Soma S. R. Banik, Xiaoxiang Deng, Edgar Davidson et al. · Nature Biotechnology | Feb 2025 | 3 |
| 22 | The CRISPR Cas patent files, part 2: Is Cpf1/Cas12a a less conflict- prone alternative to Cas9? Ulrich Storz · Journal of Biotechnology | 3 Jan 2024 | 3 |
| 23 | The Cabilly patents Ulrich Storz · mAbs | Mar 2012 | 3 |
| 24 | Patentability Requirements of Biotech Patents Ulrich Storz · SpringerBriefs in biotech patents | 19 Nov 2013 | 3 |
| 25 | Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines Raildo Duarte, Hasan Irfan Khan, Alejandro Luna et al. · Biotechnology Law Report | 25 Mar 2022 | 2 |
| 26 | Response to: Dittrich et al.: Non-Embryo-Destructive Extraction of Pluripotent Embryonic Stem Cells – Overlooked Legal Prohibitions, Professional Legal Consequences and Inconsistencies in Patent Law Timo Faltus, Ulrich Storz · Geburtshilfe und Frauenheilkunde | 21 Dec 2016 | 2 |
| 27 | Patent Landscape in Molecular Diagnostics Ulrich Storz, Wolfgang Flasche, Johanna Driehaus · SpringerBriefs in biotech patents | 2012 | 2 |
| 28 | Peptide Vaccines and Peptide Therapeutics Ulrich Storz, Wolfgang Flasche, Johanna Driehaus · SpringerBriefs in biotech patents | 2012 | 2 |
| 29 | The Limits of Patentability: Stem Cells Ulrich Storz · SpringerBriefs in biotech patents | 11 Oct 2012 | 2 |
| 30 | General Issues of Biotech Patents Andreas Hübel · SpringerBriefs in biotech patents | 2012 | 2 |
| 31 | The complex patent situation regarding antibody Fc engineering Ulrich Storz · Journal of Biotechnology | 19 Feb 2026 | 1 |
| 32 | The CRISPR Cas patent files, part 3: Prime Editing and integrase-based variants Ulrich Storz · Journal of Biotechnology | 15 Jul 2025 | 1 |
| 33 | Patent Eligibility of Stem Cells in Europe: Where do we Stand After 8 Years of Case Law? Ulrich Storz, Timo Faltus · Regenerative Medicine | 15 Dec 2016 | 1 |
| 34 | Practical Aspects of the Preparation and Filing of Patent Applications Fiona G. Bessoth · Methods in molecular biology | 4 Nov 2012 | 1 |
| 35 | Law Enforcement of Biotech Patents Martin Quodbach · SpringerBriefs in biotech patents | 19 Nov 2013 | 1 |
| 36 | Abgabe und Übernahme eines Anteils an einer medizinischen Praxis Eckhard Klapp | 1997 | 1 |
| 37 | Zusammenarbeit zwischen Krankenhäusern und Vertragsärzten – sozialrechtlich erwünscht, berufsrechtlich verboten? Kyrill Makoski · Medizinrecht | Jul 2009 | 1 |
| 38 | The Limits of Patentability: Genes and Nucleic Acids Aloys Hüttermann · SpringerBriefs in biotech patents | 11 Oct 2012 | 1 |
| 39 | Der Vermögensschaden beim Abrechnungsbetrug Frank Saliger, Michael Tsambikakis · Medizinrecht | May 2013 | 1 |
| 40 | The Limits of Patentability: Plant Biosciences Andreas Hübel · SpringerBriefs in biotech patents | 11 Oct 2012 | 1 |
| 41 | The CRISPR Cas patent files, part 4: All back to zero, think again! Ulrich Storz · Journal of Biotechnology | 23 Aug 2025 | 0 |
| 42 | An update on patent issues regarding antibody–drug conjugates Ulrich Storz · Nature Biotechnology | May 2026 | 0 |
| 43 | VALUE ADD FINANCIAL MEASURES USED BY GERMAN DAX 30 CORPORATIONS AS PART OF HIGHLY PROFESSIONALIZED CORPORATE GOVERNANCE MANAGEMENT Guenter, Grzegorz · DOAJ (DOAJ: Directory of Open Access Journals) | 2018 | 0 |
| 44 | WITHDRAWN: Moderna’s COVID 19 Patent Under the Magnifying Glass Ulrich Storz · Recent Patents on Biotechnology | 17 Jun 2022 | 0 |
| 45 | Steuerliche Fragen Eckhard Klapp | 1997 | 0 |
| 46 | Der Praxisübergabevertrag Eckhard Klapp | 1997 | 0 |
| 47 | Checkliste Eckhard Klapp | 1997 | 0 |
| 48 | Einleitung Eckhard Klapp | 1997 | 0 |
| 49 | Intellectual Property in Post-Corona Times: Managing the Future Oliver Baldus, Thomas Heinz Meitinger · American Journal of Industrial and Business Management | 2020 | 0 |
| 50 | An anisotropic continuum damage model for concrete based on biaxial experiments Alexander Michalski, Michael Brünig · PAMM | Dec 2018 | 0 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.